| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(13)62388-0 |
| P698 | PubMed publication ID | 24268611 |
| P50 | author | Paul Ridker | Q7153226 |
| Nancy Cook | Q58494310 | ||
| P2860 | cites work | Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial | Q79165142 |
| A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women | Q28218670 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 | ||
| Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 | ||
| Rosuvastatin and cardiovascular events in patients undergoing hemodialysis | Q34016806 | ||
| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra | Q34189543 | ||
| The women's health initiative observational study: baseline characteristics of participants and reliability of baseline measures | Q34272017 | ||
| Rosuvastatin in older patients with systolic heart failure | Q34710349 | ||
| Use and misuse of the receiver operating characteristic curve in risk prediction | Q40241086 | ||
| A trial-based approach to statin guidelines | Q46612105 | ||
| P433 | issue | 9907 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 1762-1765 | |
| P577 | publication date | 2013-11-20 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Statins: new American guidelines for prevention of cardiovascular disease | |
| P478 | volume | 382 |
| Q93607246 | Q93607246 |
| Q38199645 | 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial? |
| Q35776313 | 2013 ACC/AHA versus 2004 NECP ATP III Guidelines in the Assignment of Statin Treatment in a Korean Population with Subclinical Coronary Atherosclerosis |
| Q35510401 | 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque |
| Q38184962 | A Latin American perspective on the new ACC/AHA clinical guidelines for managing atherosclerotic cardiovascular disease |
| Q27691368 | A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults |
| Q28543231 | Accumulation of cardiovascular and diabetes medication among apparently healthy statin initiators |
| Q37396518 | Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population |
| Q30238752 | Addressing Knowledge Gaps in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Review of Recent Coronary Artery Calcium Literature |
| Q46059888 | Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide |
| Q38680214 | Adult Height, Prevalent Coronary Calcium Score, and Incident Cardiovascular Outcomes in a Multi-Ethnic Cohort |
| Q35776957 | Agreement Between Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 Peruvian Sites |
| Q35553113 | An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort |
| Q40814229 | Applicability of the 2013 ACC/AHA Risk Assessment and Cholesterol Treatment Guidelines in the real world: results from a multiethnic case-control study |
| Q88166883 | Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged? |
| Q37612171 | Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study |
| Q33916879 | Assessing the performance of the Framingham Stroke Risk Score in the reasons for geographic and racial differences in stroke cohort |
| Q37438420 | Assessment of Coronary Artery Calcium Scoring for Statin Treatment Strategy according to ACC/AHA Guidelines in Asymptomatic Korean Adults |
| Q35582127 | Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort |
| Q33724722 | Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol |
| Q35025720 | Biomarkers of cardiovascular disease risk in women |
| Q90055871 | Biomimetic nanoparticle technology for cardiovascular disease detection and treatment |
| Q57152613 | Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit-Based Lipid and Blood Pressure Treatment |
| Q33807154 | Can I get a guideline to help me interpret treatment guidelines? |
| Q36193205 | Can cardiovascular disease guidelines that advise treatment decisions based on absolute risk be improved? |
| Q60614572 | Cardiac Prevention Guidelines |
| Q97639351 | Cardiorespiratory fitness improves prediction of mortality of standard cardiovascular risk scores in a Latino population |
| Q87651962 | Cardiovascular Disease Risk Score: Results from the Filipino-American Women Cardiovascular Study |
| Q26795419 | Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events |
| Q33848763 | Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. |
| Q47592068 | Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry |
| Q92464675 | Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment |
| Q26777866 | Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? |
| Q61805608 | Cardiovascular risk algorithms in primary care: Results from the DETECT study |
| Q26738461 | Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach |
| Q35595708 | Cardiovascular risk perception in women: true unawareness or risk miscalculation? |
| Q47101654 | Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline |
| Q35007546 | Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey |
| Q35070830 | Clinician's guide to the updated ABCs of cardiovascular disease prevention |
| Q37090741 | Comparative Effectiveness of Personalized Lifestyle Management Strategies for Cardiovascular Disease Risk Reduction |
| Q35028514 | Comparative accuracy of different risk scores in assessing cardiovascular risk in Indians: a study in patients with first myocardial infarction |
| Q36168695 | Comparing Guidelines for Statin Treatment in Canada and the United States |
| Q37006890 | Comparison of risk scores for the prediction of stroke in African Americans: Findings from the Jackson Heart Study |
| Q58704552 | Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia |
| Q34980772 | Consensus statement on management of dyslipidemia in Indian subjects |
| Q36701872 | Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease |
| Q38538716 | Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies |
| Q33638988 | Current guidelines on prevention with a focus on dyslipidemias |
| Q38627117 | Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials |
| Q38912710 | Diagnosis and risk stratification of women with stable ischemic heart disease |
| Q35814972 | Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis |
| Q62711546 | Discordance between 10-year cardiovascular risk estimates using the ACC/AHA 2013 estimator and coronary artery calcium in individuals from 5 racial/ethnic groups: Comparing MASALA and MESA |
| Q61818215 | Discrimination between Obstructive Coronary Artery Disease and Cardiac Syndrome X in Women with Typical Angina and Positive Exercise Test; Utility of Cardiovascular Risk Calculators |
| Q26765157 | Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies |
| Q45325771 | Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs |
| Q26783435 | Effects of Vaccinium Berries on Serum Lipids: A Meta-Analysis of Randomized Controlled Trials |
| Q88994510 | Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy |
| Q89538473 | Estimation of Cardiovascular Risk from Self-Reported Knowledge of Risk Factors: Insights from the Minnesota Heart Survey |
| Q90433403 | Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative |
| Q64055778 | External validation of pooled cohort equations using systolic blood pressure intervention trial data |
| Q35379591 | Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study |
| Q38195221 | HDL hypothesis: where do we stand now? |
| Q34795273 | Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines |
| Q40069426 | Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy. |
| Q22241921 | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association |
| Q30238784 | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association |
| Q36119239 | Impact of clinical input variable uncertainties on ten-year atherosclerotic cardiovascular disease risk using new pooled cohort equations |
| Q42339042 | Implementing Cardiovascular Risk Prediction in Clinical Practice: The Future Is Now. |
| Q36085712 | Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort |
| Q35142002 | Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA) |
| Q35158163 | Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. |
| Q35940811 | Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators |
| Q35573159 | Interaction analysis of the new pooled cohort equations for 10-year atherosclerotic cardiovascular disease risk estimation: a simulation analysis. |
| Q38214386 | Investigational therapies for the treatment of atherosclerosis |
| Q38411529 | Longitudinal hyperlipidemia outcomes at three student-run free clinic sites |
| Q87727852 | Looking back, looking forward |
| Q62492154 | Machine Learning Outperforms ACC / AHA CVD Risk Calculator in MESA |
| Q39255905 | Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground? |
| Q38344129 | Management of lipid disorders in patients living with HIV. |
| Q42855740 | Medical decision making and the counting of uncertainty |
| Q36987455 | Medication Use by Race and Ethnicity in Women Transitioning Through the Menopause: A Study of Women's Health Across the Nation Drug Epidemiology Study |
| Q28079470 | Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases |
| Q37306497 | Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. |
| Q40266203 | Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts |
| Q51749272 | New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. |
| Q34982921 | New Pooled Cohort Risk equations: application to a recent stroke patient population |
| Q48068042 | New cholesterol guidelines and the secondary prevention of cardiovascular disease - a commentary on epistemic aspects. |
| Q33603183 | New cholesterol guidelines: worth the wait? |
| Q26786829 | Obesity and cancer: mechanistic insights from transdisciplinary studies |
| Q41458408 | On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate |
| Q96576353 | Organic NIR-II molecule with long blood half-life for in vivo dynamic vascular imaging |
| Q28069411 | Overview of guidelines for the management of dyslipidemia: EU perspectives |
| Q38338236 | PCSK9 inhibition: current concepts and lessons from human genetics |
| Q26991787 | Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines |
| Q38896998 | Performance of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations by Social Deprivation Status |
| Q60952997 | Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation |
| Q52607834 | Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals. |
| Q33555412 | Perspective on the 2013 American Heart Association/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals |
| Q47130405 | Pharmacogenetics in Cardiovascular Medicine |
| Q92878618 | Physicians Voluntarily Using an EHR-Based CDS Tool Improved Patients' Guideline-Related Statin Prescription Rates: A Retrospective Cohort Study |
| Q35155062 | Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines |
| Q33584697 | Prediction of atherosclerotic cardiovascular disease mortality in a nationally representative cohort using a set of risk factors from pooled cohort risk equations |
| Q39377772 | Prediction of hard cardiovascular events in HIV patients |
| Q40200947 | Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys. |
| Q38295069 | Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations |
| Q27002928 | Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective |
| Q90102175 | Protein Biomarkers of Cardiovascular Disease and Mortality in the Community |
| Q40478455 | Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. |
| Q45084705 | QRISK2 validation by ethnic group |
| Q47713050 | Real-Time and High-Resolution Bioimaging with Bright Aggregation-Induced Emission Dots in Short-Wave Infrared Region |
| Q34364949 | Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction. |
| Q36161516 | Recalibration of the ACC/AHA Risk Score in Two Population-Based German Cohorts |
| Q36873040 | Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines |
| Q37240652 | Reduced Kidney Function Is Associated With Cardiometabolic Risk Factors, Prevalent and Predicted Risk of Cardiovascular Disease in Chinese Adults: Results From the REACTION Study |
| Q87295524 | Refining the American guidelines for prevention of cardiovascular disease |
| Q87295526 | Refining the American guidelines for prevention of cardiovascular disease |
| Q87295528 | Refining the American guidelines for prevention of cardiovascular disease |
| Q87295530 | Refining the American guidelines for prevention of cardiovascular disease - Authors' reply |
| Q50461245 | Refining the American guidelines for prevention of cardiovascular disease. |
| Q39612048 | Relation of longitudinal changes in body mass index with atherosclerotic cardiovascular disease risk scores in middle-aged black and white adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study |
| Q46667834 | Risk factors: new risk-assessment guidelines-more or less personalized? |
| Q53756517 | Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a moder |
| Q36642851 | Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). |
| Q92021212 | Schnyder corneal dystrophy-associated UBIAD1 mutations cause corneal cholesterol accumulation by stabilizing HMG-CoA reductase |
| Q33704011 | Screening strategies for cardiovascular disease in asymptomatic adults |
| Q38248457 | Secondary prevention of stroke in the elderly: focus on drug therapy |
| Q40675155 | Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease? |
| Q33984469 | Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example |
| Q38839561 | Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction |
| Q89093455 | Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis) |
| Q38721111 | Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. |
| Q40455288 | Statin prescribing according to gender, age and indication: what about the benefit-risk balance? |
| Q86525606 | Statin treatment for older adults: the impact of the 2013 ACC/AHA cholesterol guidelines |
| Q34566869 | Statinopause |
| Q35875819 | Statins Provide Less Benefit in Populations with High Noncardiovascular Mortality Risk: Meta-Regression of Randomized Controlled Trials |
| Q35576102 | Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis |
| Q38392235 | Statins and aspirin: do they really work in women? |
| Q99622989 | Statins in primary prevention: is the enthusiasm justified? |
| Q44894905 | Statins, risk assessment, and the new American prevention guidelines |
| Q99207879 | Statins-based prophylactic mouthwash and nasal spray may protect against COVID-19 |
| Q26783226 | Statins: Cholesterol guidelines and Indian perspective |
| Q35793619 | Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effective |
| Q28601636 | Study of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health Study |
| Q48130880 | Systems Pharmacology Dissection of the Protective Effect of Myricetin Against Acute Ischemia/Reperfusion-Induced Myocardial Injury in Isolated Rat Heart. |
| Q38825508 | Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk |
| Q38985960 | Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease |
| Q45353400 | The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography |
| Q42418260 | The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cholesterol management and for cardiovascular risk stratification: a reappraisal |
| Q46559317 | The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. |
| Q33917513 | The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women |
| Q35762868 | The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape |
| Q52560846 | The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel. |
| Q38649376 | The Veterans Affairs Cardiac Risk Score: Recalibrating the Atherosclerotic Cardiovascular Disease Score for Applied Use. |
| Q35204645 | The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores |
| Q91607022 | The effects of statins on dental and oral health: a review of preclinical and clinical studies |
| Q86270449 | The new ACC/AHA guidelines on the treatment of dyslipidemia: cons |
| Q42342408 | The new cholesterol and blood pressure guidelines: perspective on the path forward |
| Q38267131 | The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know |
| Q36331639 | The new lipid guidelines: what do primary care clinicians think? |
| Q50904903 | The pseudo-high-risk prevention strategy. |
| Q28654209 | The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion |
| Q50973066 | Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. |
| Q86934450 | Treating our way out of AIDS? |
| Q53678430 | Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. |
| Q51736225 | Twenty-year trends in cardiovascular risk among men and women in the United States. |
| Q36355669 | Use and Customization of Risk Scores for Predicting Cardiovascular Events Using Electronic Health Record Data |
| Q36052754 | Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. |
| Q47263832 | Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S. |
| Q34307407 | Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations |
| Q87764761 | [New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group o |
Search more.